Processing your payment...
Please do not close your browser.

Congenital Hyperinsulinism Drugs Market- Global Growth, Trends and Forecast (2022 - 2029) By Type (Diffuse Hyperinsulinism and Focal Hyperinsulinism) By Route of Administration (Intravenous, Oral, Parenteral) and By Regions

28 Jun, 2022 | 105 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the Congenital Hyperinsulinism Drugs Market will register a CAGR of 4.5 % in terms of revenue and the global market size will reach USD xx Billion by 2029.

Congenital Hyperinsulinism Drugs Market Overview

The Congenital Hyperinsulinism market outlook analyses the impact of current Congenital Hyperinsulinism therapies on the market, unmet needs, drivers and barriers, and demand for better technology to help build a detailed understanding of historic, current, and forecasted Congenital Hyperinsulinism market trends.

An uncommon genetic disorder known as congenital hyperinsulinism (CHI) causes individuals to have elevated amounts of insulin, a hormone that aids in blood sugar regulation. People who have this illness frequently experience low blood sugar episodes (hypoglycemia). These episodes affect young children between the ages of 1 and 12 and are characterized by lethargy, irritability, and nausea. The episodes' consistency causes a surge in major side effects like anorexia, seizures, intellectual incapacity, and eyesight loss.

This congenital hyperinsulinism market provides information on market share, new developments and product pipeline analysis, the impact of domestic and localized market players, analyses of opportunities in terms of developing revenue pockets, adjustments to market regulations, product approvals, strategic choices, product launches, geographic expansions, and technological innovations in the market.

What is our Congenital Hyperinsulinism Drugs Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 4.5 % during the review period (2022 to 2029).

 

By Type

  • Diffuse Hyperinsulinism 
  • Focal Hyperinsulinism

 

By Route of Administration

 

 

 

 

  • Intravenous
  • Oral
  • Parenteral

By End-User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

 

 

 

By Companies

  • Zealand Pharma A/S,
  • REZOLUTE, INC,
  • Xeris Pharmaceuticals, Inc,
  • Eiger BioPharmaceuticals.
  • RECORDATI
  • IVAX Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd
  • AmideBio LLC
  • e5 Pharma, LLC
  • Pfizer Inc, Biocon Limited
  • Sanofi
  • Eli Lilly and Company
  • Novartis India
  • Novo Nordisk A/S
  • Cipla Inc, Abbott
  • Torrent Pharmaceuticals Ltd
  • Cadila Pharmaceuticals
  • Others

 

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

 

Historical Year

 

2017 to 2021

Forecast Year

2022 to 2029

Number of Pages

105

 

Customization Available

 

Yes, the report can be customized as per your needs

Who are the Major Players in the Congenital Hyperinsulinism Drugs Market?

Market Growth Reports lists out all the Congenital Hyperinsulinism Drugs Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Zealand Pharma A/S, REZOLUTE, INC, Xeris Pharmaceuticals, Inc, Eiger BioPharmaceuticals., RECORDATI, IVAX Pharmaceuticals, Teva Pharmaceutical Industries Ltd, AmideBio LLC, e5 Pharma, LLC, Pfizer Inc, Biocon Limited, Sanofi, Eli Lilly and Company, Novartis India, Novo Nordisk A/S, Cipla Inc, Abbott, Torrent Pharmaceuticals Ltd, Cadila Pharmaceuticals, Others.

Industry News:

AMIDEBIO Awarded $1.56M SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism

September 30, 2019, AmideBio, LLC, a privately-held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The goal of this two-year grant is to enable an Investigational New Drug (IND) filing with the FDA of a clinical candidate for the long-term treatment of congenital hyperinsulinism. Several promising glucagon analogs were identified during the Phase 1 SBIR, and the Phase II grant will enable the final selection of a clinical candidate and the preparation of an IND.

What are the major A Type, Route of Administration, and End Users for the Congenital Hyperinsulinism Drugs Market?

By Type, it is segmented into

  • Diffuse Hyperinsulinism 
  • Focal Hyperinsulinism

By Route of Administration, it is segmented into

  • Intravenous
  • Oral
  • Parenteral

By End User, it is segmented into

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Congenital Hyperinsulinism Drugs Market Regional Analysis

Due to the rising number of CHI cases in Canada, the accessibility of healthcare policies, and continuing clinical studies, North America is anticipated to have the greatest market share globally. Due to the introduction of newborn screening, the construction of healthcare facilities in rural regions, and the existence of unexplored market potential, Asia Pacific is anticipated to have the quickest growth in the market.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. INTRODUCTION
    • MARKET DEFINITION
    • MARKET DYNAMICS
    • MARKET SEGMENTATION
    • REPORT TIMELINES
    • KEY STAKEHOLDERS
  2. RESEARCH METHODOLOGY
    • DATA MINING
      • SECONDARY RESEARCH
      • PRIMARY RESEARCH
      • SUBJECT MATTER EXPERT ADVICE
    • QUALITY CHECK
    • FINAL REVIEW
      • DATA TRIANGULATION
      • BOTTOM-UP APPROACH
      • TOP-DOWN APPROACH
      • RESEARCH FLOW
  3. EXECUTIVE SUMMARY
    • INTRODUCTION
    • GLOBAL CONGENITAL HYPERINSULINISM DRUGS MARKET BY TYPES
    • GLOBAL CONGENITAL HYPERINSULINISM DRUGS MARKET BY MECHANISM OF ACTION
    • GLOBAL CONGENITAL HYPERINSULINISM DRUGS MARKET BY APPLICATION
  4. MARKET DYNAMICS
    • DRIVERS
      • INCREASING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASE
    • RESTRAINTS
      • STRINGENT ENVIRONMENTAL REGULATIONS
      • HIGH COST OF MATERIALS
    • OPPORTUNITIES
      • CONGENITAL HYPERINSULINISM DRUGS GROWTH
    • APPLICATION OF CONGENITAL HYPERINSULINISM DRUGS IMPACT ON COVID 19
  5. GLOBAL CONGENITAL HYPERINSULINISM DRUGS MARKET, BY TYPES
    • INTRODUCTION
    • ZEJULA
    • LYNPARZA
    • RUBRACA
    • TALZENNA
  6. GLOBAL CONGENITAL HYPERINSULINISM DRUGS MARKET, BY MECHANISM OF ACTION
    • INTRODUCTION
    • BASE EXCISION REPAIR (BER)
    • HOMOLOGOUS RECOMBINATION (HR)
    • MISMATCH REPAIR (MMR)
    • OTHERS
  7. GLOBAL CONGENITAL HYPERINSULINISM DRUGS MARKET, BY APPLICATION
    • INTRODUCTION
    • OVARIAN CANCER
    • BREAST CANCER
    • OTHERS
  8. GLOBAL CONGENITAL HYPERINSULINISM DRUGS MARKET, BY REGION
    • NORTH AMERICA
      • US
      • CANADA
      • MEXICO
    • EUROPE
      • GERMANY
      • FRANCE
      • UK
      • ITALY
      • RUSSIA
      • REST OF EUROPE
    • APAC
      • CHINA
      • SOUTH KOREA
      • JAPAN
      • INDIA
      • AUSTRALIA
      • ASEAN
      • REST OF APAC
    • MIDDLE EAST AND AFRICA
      • SAUDI ARABIA
      • UAE
      • SOUTH AFRICA
      • TURKEY
      • REST OF MEA
    • SOUTH AMERICA
      • BRAZIL
      • REST OF MEA
      • ARGENTINA
      • REST OF SOUTH AMERICA
  9. COMPETITIVE LANDSCAPE
    • MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    • AND AGREEMENTS
      • KEY DEVELOPMENT
    • MARKET SHARE PERCENT/RANKING ANALYSIS
    • STRATEGIES ADOPTED BY LEADING PLAYERS
  10. COMPANY PROFILES
    • BUSINESS OVERVIEW
    • COMPANY SNAPSHOT
    • PRODUCT BENCHMARKING
    • STRATEGIC INITIATIVES
  1. ARTIOS PHARMA
  2. ASTRAZENECA
  3. JOHNSON & JOHNSON SERVICES, INC.
  4. BRISTOL-MYERS SQUIBB COMPANY
  5. GLAXOSMITHKLINE
  6. CLOVIS ONCOLOGY
  7. PFIZER INC

 

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla